Schmidt M, et al. Ann. Oncol. (2010) cited as Ref 564 in DOI: 10.1038/s41392-020-0110-5 (Q9827)
Revision as of 22:04, 20 May 2020 by Admin (talk | contribs) (Created claim: Property:P93: An open-label randomized phase II study of adecatumumab a fully human anti-EpCAM antibody as monotherapy in patients with metastatic breast cancer, #quickstatements; #temporary_batch_1590010982689)
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Schmidt M, et al. Ann. Oncol. (2010) cited as Ref 564 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Schmidt M
0 references
2010
0 references
Ann. Oncol.
0 references
21
0 references
An open-label randomized phase II study of adecatumumab a fully human anti-EpCAM antibody as monotherapy in patients with metastatic breast cancer (English)
0 references
